# Is Cation Exchange Chromatography the Bottleneck Defining Modern mAb Manufacturing?

Protein A capture alone can no longer guarantee the purity standards modern monoclonal antibody programs demand — and cation exchange (CEX) chromatography is filling that gap. As upstream mammalian cell culture systems generate increasingly dense, impurity-laden product streams, [downstream processing](https://synbiointel.com/glossary/downstream-processing) has become the rate-limiting constraint in biopharmaceutical manufacturing. Complex mAb formats including bispecific antibodies, antibody-drug conjugates (ADCs), and Fc fusion proteins can exit Protein A capture at purity levels below 80%, according to reporting in *Genetic Engineering & Biotechnology News* (GEN). That purity deficit must be recovered downstream — and CEX, with its charge-based separation mechanism, is the primary tool doing that work.

The mechanism is well understood: under mildly acidic conditions, mAbs carry a net positive charge and bind to negatively charged resin media, while impurities with lower isoelectric points (pIs) interact differently and can be selectively eluted. As Alejandro Becerra, PhD, principal applications scientist and global purification technical lead at Thermo Fisher Scientific, explains: "Cation exchange chromatography is one of the key polishing steps because antibodies have relatively high isoelectric points, or pIs, and many impurities have lower pIs."

The implication for process development teams is direct: CEX is not a legacy backup step — it is the precision instrument resolving what affinity capture leaves behind.

---

## Why Rising Upstream Titers Are Creating a Downstream Crisis

The productivity gains of the past decade in mammalian cell culture have been substantial, but they have transferred pressure rather than eliminated it. Denser product streams carry proportionally heavier impurity loads across two categories:

**Process-related impurities** include host cell proteins (HCPs), residual DNA, and viral contaminants introduced during cell culture production.

**Product-related impurities** originate from the molecule itself — aggregates, fragments, and charge variants that arise during cell culture, downstream processing, or within the chromatography columns.

As mAb formats grow more structurally complex — bispecific antibodies, ADCs, engineered scaffolds — molecular heterogeneity increases further. These variants can be structurally nearly indistinguishable from the target molecule, making separation technically demanding.

Anion exchange chromatography (AEX) handles some of this load and is described in the GEN piece as "somewhat standardized," but the article's key argument is that the increased impurity burden of complex feed streams requires intermediate polishing that AEX alone cannot provide. CEX fills that intermediate role.

---

## The Aggregate Problem: No Universal Spec, High Regulatory Stakes

High molecular weight (HMW) aggregates represent one of the most critical quality attributes in mAb manufacturing — and one of the most difficult to resolve. These multimers are structurally similar to the target antibody, making them resistant to affinity-based removal.

"Aggregates can form during production, and they are a key measure of product quality," says David Brown, PhD, associate director, process development at KBI Biopharma. "Purity is one of the main product-quality measures that we look for."

Critically, there is no universal regulatory threshold. According to the GEN source, acceptable aggregate levels are determined program-by-program based on safety, efficacy, and stability data. Some programs require levels below 2%, others below 1%, and some accept levels as high as 4–5%. This variability places the analytical and process development burden squarely on the drug sponsor — and makes robust CEX method development a competitive differentiator, not just a compliance checkbox.

Hydrophobic interaction chromatography (HIC) can address aggregates and HCPs in some workflows, but the GEN piece positions CEX as "the more common and powerful tool" for charge variants and impurities with similar pIs to the target molecule.

---

## What This Means for Process Development Strategy

The shift has structural implications for how [CDMO](https://synbiointel.com/glossary/cdmo) teams and in-house process development groups approach platform design:

**1. Affinity capture is not a complete solution for complex formats.** For bispecific antibodies, ADCs, and Fab fragments, accepting that Protein A purity will be sub-80% and designing CEX to compensate is now a realistic process architecture decision — not a failure of upstream optimization.

**2. Resin selection matters more as molecule complexity increases.** The GEN piece notes that by "correctly choosing a suitable CEX resin and systematically developing the appropriate operating conditions, challenging impurities can be separated and removed." Resin chemistry, mobile phase composition, and pH gradient control are all variables that require empirical development — suggesting that high-throughput screening of resin candidates early in development provides compounding returns.

**3. Data-driven process development is becoming standard practice.** The GEN summary references "data-driven strategies" as a defining feature of modern CEX deployment. For development teams managing multiple mAb candidates simultaneously, systematic process characterization data — particularly binding capacity, selectivity under varying pH and conductivity conditions — informs platform transferability and reduces tech transfer risk at clinical-grade manufacturing scale.

**4. The impurity burden will continue to grow.** As antibody engineering pushes toward more complex scaffolds and higher-order conjugates, the structural heterogeneity of product streams will increase. A well-developed CEX unit operation is described in the GEN article as able to "advance a candidate molecule toward clinical use" — positioning it as a platform competency, not a one-off method.

---

## Skeptical Read: Sponsored Content Limits, But Core Argument Holds

This GEN article carries a "sponsored" tag, which signals involvement from a vendor — likely Thermo Fisher Scientific, given the named quote from their principal applications scientist. That framing warrants caution: specific resin product claims, performance numbers, or head-to-head comparisons with competing resins should be treated as promotional unless independently replicated.

That said, the underlying technical argument is structurally sound and consistent with the published bioprocess literature. The observation that complex mAb formats exit Protein A at lower purity and require robust polishing is not vendor-specific. Nor is the challenge of resolving charge variants and aggregates from structurally similar target molecules. The below-80% purity figure for complex formats after affinity capture, and the program-specific aggregate thresholds (1–5%), are cited as reported facts from the source and reflect widely observed industry dynamics.

The article does not resolve the more commercially interesting question: which resin chemistries or operating strategies are actually delivering the best selectivity for specific impurity classes in 2026. That data, if it exists, is not surfaced here.

---

## Key Takeaways

- Complex mAb formats including bispecifics, ADCs, and Fc fusions can exit Protein A capture at purity below 80%, per GEN reporting — shifting the quality burden to CEX polishing steps.
- CEX separates impurities from target mAbs via charge-based interactions; antibodies' characteristically high pIs allow selective binding under mildly acidic conditions while lower-pI impurities are removed.
- HMW aggregates are a primary CEX target because they are structurally similar to the desired antibody; acceptable levels range from below 1% to as high as 4–5% depending on the program, with no universal regulatory threshold.
- AEX is described as "somewhat standardized" while CEX is positioned as the more powerful intermediate polishing tool for complex, high-impurity feed streams.
- The source carries a sponsored label tied to Thermo Fisher Scientific — vendor-specific performance claims require independent validation.

---

## Frequently Asked Questions

**What is CEX chromatography and why is it used in mAb purification?**
Cation exchange (CEX) chromatography separates molecules based on charge. Under mildly acidic conditions, monoclonal antibodies carry a net positive charge and bind to negatively charged resin, while impurities with lower isoelectric points interact differently and can be removed. It is used as a polishing step after affinity capture because it can resolve charge variants, aggregates, and other product-related impurities that structurally resemble the target antibody.

**Why can't Protein A chromatography alone purify complex mAbs?**
Protein A affinity capture is highly effective for conventional IgG formats but delivers significantly lower purity for complex molecules such as bispecific antibodies, ADCs, Fab fragments, and Fc fusion proteins — sometimes below 80% purity. These formats lack the standard Fc region geometry Protein A exploits, or carry additional structural complexity that generates more product-related impurities at the capture stage.

**What aggregate levels are acceptable in monoclonal antibody drug products?**
There is no single regulatory standard. According to the GEN source, acceptable HMW aggregate levels are determined on a program-by-program basis. Some programs require below 2%, others below 1%, and some accept levels as high as 4–5%, depending on safety, efficacy, and stability data specific to the molecule.

**How does CEX differ from AEX in mAb downstream processing?**
Anion exchange chromatography (AEX) is described as relatively standardized and handles some impurity classes. CEX is positioned as the more powerful and flexible intermediate polishing tool, particularly for removing charge variants and impurities with pIs close to the target molecule — a challenge that increases as mAb formats grow more complex.

**What is driving renewed interest in CEX chromatography in 2026?**
Two converging trends: upstream productivity gains have generated denser, more complex product streams; and the expansion of mAb modalities beyond conventional IgGs has increased molecular heterogeneity. Both trends amplify the impurity challenge that CEX is designed to address, making it a more critical step in modern biopharmaceutical manufacturing workflows.